Esphera SynBio Analysis: $2M Raised
What is Esphera SynBio?
Esphera SynBio develops next-generation cancer treatments using a proprietary in vivo transgene platform that modifies tumor cells to produce immunostimulatory exosomes. These modified exosomes function as bespoke, patient-specific cancer vaccines generated directly within the tumor microenvironment. The technology enables the reprogramming of protumorigenic exosomes into antigen-bearing, immunostimulatory vesicles that activate the body's immune response against cancer.
Location
Ottawa, Canada
Employees
11-50
Founded
2022
Funding Status
Seed
Product Features & Capabilities
- In vivo transgene platform modifying tumor cells to produce modified exosomes
- Exosomes with surface targeting moieties and luminal protein/RNA payloads
- Patient-specific cancer vaccines generated within tumor microenvironment
- Therapeutic exosomes with extravesicular targeting domains and antigen-carrying capacity
Use Cases
Modify tumor cells in vivo to generate patient-specific cancer vaccines; Reprogram immunosuppressive tumor-derived exosomes into immunostimulatory vesicles; Deliver targeted protein or RNA payloads to tumor sites via modified exosomes; Create antigen-bearing exosomes that activate T-cell responses; Enable off-the-shelf cancer immunotherapy with personalized treatment delivery
Other Considerations
Founded in 2022; HQ in Ottawa, ON; Current investors: GKCC LLC and FACIT; Raising Series A in 2025; Technology platform enables in vivo generation of patient-specific cancer vaccines; Platform shows promise in broader immunomodulation applications beyond oncology
See something that needs updating? Suggest edits to this profile.